Efficacy and safety of entecavir (ETV) vs. adefovir (ADV) in chronic hepatitis B (CHB) patients with evidence of hepatic decompensation: ETV-048 study

被引：0
|
作者：
Liaw, Y. F. [1 ]
Raptopoulou-Gigi, M. [2 ]
Cheinquer, H. [3 ]
Sarin, S. K. [4 ]
Tanwandee, T. [5 ]
Leung, N. [6 ]
Myers, R. P. [7 ]
Brown, R. S., Jr. [8 ]
Bialkowska, J.
Munafo, L.
Chen, Y. C.
Tang, S.
Cooney, E.
Dharane, P.
Newman, J.
机构：
[1] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Guishan, Taiwan
[2] Aristotle Univ Thessaloniki, Dept Internal Med, Thessaloniki, Greece
[3] Univ Fed Rio Grande do Sul, BR-90046900 Porto Alegre, RS, Brazil
[4] GB Pant Hosp, Dept Gastroenterol, Delhi, India
[5] Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok 10700, Thailand
[6] Alice Ho Miu Ling Nethersole Hosp, Tai Po, Hong Kong, Peoples R China
[7] Univ Calgary, Liver Unit, Calgary, AB T2N 1N4, Canada
[8] Columbia Univ, Med Ctr, Ctr Liver Dis & Transp, New York, NY 10027 USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2010年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A125 / A125
页数：1
相关论文
共 50 条
  • [31] PROFOUND VIROLOGIC RESPONSE IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH ENTECAVIR (ETV) IN HBEAG POSITIVE AND NEGATIVE DISEASE
    Baqai, Sumbella F.
    Yi, Debbie Hana
    Gish, Robert G.
    HEPATOLOGY, 2009, 50 (04) : 530A - 530A
  • [32] Efficacy and safety of two years therapy with adefovir dipivoxil (ADV) in Chinese patients with HBeAg positive chronic hepatitis B (CHB)
    Mao, Yiming
    Zeng, Minde
    Yao, Guangbi
    Xu, Daozhen
    Hou, Jinlin
    Chen, Yagang
    Dixon, Jon S.
    Barker, Keith F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A14 - A15
  • [33] Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901
    Manns, Michael P.
    Akarca, Ulus S.
    Chang, Ting-Tsung
    Sievert, William
    Yoon, Seung Kew
    Tsai, Naoky
    Min, Albert
    Pangerl, Andreas
    Beebe, Suzanne
    Yu, Miao
    Wongcharatrawee, Suchat
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (03) : 361 - 368
  • [34] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    De Man, R. A.
    Mutimer, D.
    Gish, R.
    Chang, T.
    Zhu, J.
    Cross, A.
    Brett-Smith, H.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S89 - S89
  • [35] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Sollano, J.
    De Man, R. A.
    Mutimer, D.
    Gish, R. G.
    Chang, T. -T.
    Zhu, J.
    Cross, A.
    Brett-Smith, H.
    LIVER INTERNATIONAL, 2006, 26 : 6 - 7
  • [36] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Chang, Ting-Tsung
    Chao, You-Chen
    Sollano, Jose
    Han, Kwang-Hyub
    Lai, Ching-Lung
    Lao-Tan, Judy
    Akbar, Nurul
    Zhu, Jin
    Cross, Anne
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A33 - A33
  • [37] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Chang, Ting-Tsung
    Chao, You-Chen
    Sollano, Jose
    Han, Kwang-Hyub
    Lai, Ching-Lung
    Lao-Tan, Judy
    Akbar, Nurul
    Zhu, Jin
    Cross, Anne
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A89 - A89
  • [38] ENTECAVIR (ETV) MONOTHERAPY FOR 96 WEEKS IS COMPARABLE TO COMBINATION THERAPY WITH ETV PLUS TENOFOVIR (TDF) IN NUCLEOS(T)IDE-NAiVE PATIENTS WITH CHRONIC HEPATITIS B (CHB): THE BELOW STUDY
    Lok, Anna S.
    Trinh, Huy N.
    Carosi, Giampiero
    Akarca, Ulus S.
    Gadano, Adrian
    Habersetzer, Francois
    Sievert, William
    Wong, David K.
    Lovegren, Meghan
    Zhang, Hui
    Llamoso, Cyril
    HEPATOLOGY, 2011, 54 : 471A - 471A
  • [39] Efficacy and safety of Adefovir for the treatment of patients with chronic hepatitis B (CHB) resistant to lamivudine in Spain
    Buti, M
    Esteban, R
    Escartin, P
    Calleja, JL
    Enriquez, J
    Pons, F
    Crespo, J
    Bengoechea, MG
    Prieto, M
    Casanovas, T
    Samaniego, JG
    Miras, M
    Roldan, FP
    Pelaez, M
    Fraga, E
    Moreira, V
    Carro, PG
    Rueda, M
    JOURNAL OF HEPATOLOGY, 2004, 40 : 125 - 125
  • [40] Long :Term Histologic Improvement with Entecavir (ETV) Therapy in Patients with Chronic Hepatitis B (CHB) from Japanese and Worldwide Development Programs
    Liaw, Yun-Fan
    Chang, Ting-Tsung
    Wu, Shun-Sheng
    Schill, Eugene R.
    Han, Kwang-Hyub
    Lai, Ching-Lung
    Safadi, Rifaat
    Lee, Samuel S.
    Halota, Waldemar
    Goodman, Zachary D.
    Zhang, Hui
    Iloeje, Uchenna H.
    Beebe, Suzanne
    Kreter, Bruce
    Ishikawa, Hiroki
    Katano, Yoshiaki
    Takaguchi, Koichi
    Omata, Masao
    GASTROENTEROLOGY, 2009, 136 (05) : A798 - A799
12345